Skip to main content

Advertisement

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Fig. 1

Kaplan–Meier survival curve for maintaining bDMARD-free remission after discontinuation of different types of bDMARDs. X axis represents days after bDMARD discontinuation. Y axis represents rates of maintained BFR. BFR failure defined if DAS28-CRP exceeded 2.3 or if bDMARDs restarted. If disease activity not available for more than 6 months, patient was regarded as censored case at date of last disease activity record. Kaplan–Meier method used to estimate BFR maintenance time. bDMARD biological disease-modifying antirheumatic drug, BFR biological disease-modifying antirheumatic drug-free remission, TNFi(mAb) monoclonal antibodies against TNF (infliximab, adalimumab, and golimumab), TNFi(R/P) soluble TNF receptor or Fab fragments against TNF fused with polyethylene glycol (etanercept and certolizumab), CTLA4-Ig abatacept, IL-6Ri interleukin-6 receptor inhibitor (tocilizumab), CI confidence interval, TNF tumor necrosis factor

Back to article page